Role of microRNAs in the reperfused myocardium towards post-infarct remodelling

Cardiovascular Research

Volumn 94, Issue 2, 2012, Pages 284-292

  Zhu, Hongyan ^a   Fan, Guo Chang ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Ischaemia reperfusion; MicroRNA; Myocardial infarction; Post infarct remodelling

Indexed keywords

MICRORNA; MIR 1; MIR 126; MIR 133; MIR 199A; MIR 21; MIR 210; MIR 24; MIR 29; MIR 320; MIR 494; MIR 499; MIR 92A; UNCLASSIFIED DRUG;

HEART; HEART MUSCLE; HEART MUSCLE INJURY; HEART MUSCLE REPERFUSION; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; HUMANS; MICRORNAS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; VENTRICULAR REMODELING;

EID: 84860145591     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr291     Document Type: Review

References (99)

1. Hori M, Nishida K. Oxidative stress and left ventricular remodeling after myocardial infarction. Cardiovasc Res 2009;81:457-464.
2. Landmesser U, Wollert KC, Drexler H. Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res 2009;81:519-527.
3. Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res 2009;81:482-490.
4. Takemura G, Nakagawa M, Kanamori H, Minatoguchi S, Fujiwara H. Benefits of reperfusion beyond infarct size limitation. Cardiovasc Res 2009;83:269-276.
5. Eefting F, Rensing B, Wigman J, Pannekoek WJ, Liu WM, Cramer MJ et al. Role of apoptosis in reperfusion injury. Cardiovasc Res 2004;61:414-426. (Pubitemid 38210148)
6. Piper HM, García-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 1998;38:291-300. (Pubitemid 28294147)
7. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993;21: 537-545. (Pubitemid 23047942)
8. Downey JM, Cohen MV. Why do we still not have cardioprotective drugs? Circ J 2009; 73:1171-1177.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116: 281-297.
10. Wang Z. MicroRNA: a matter of life or death. World J Biol Chem 2010;1:41-54.
11. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20. (Pubitemid 40094598)
12. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136: 215-233.
13. Ambros V. microRNAs: tiny regulators with great potential. Cell 2001;107:823-826.
14. Liu N, Olson EN. MicroRNA regulatory networks in cardiovascular development. Dev Cell 2010;18:510-525.
15. Fazi F, Nervi C. MicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determination. Cardiovasc Res 2008;79:553-561.
16. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006;103:18255-18260. (Pubitemid 44871645)
17. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD et al. Altered microRNA expression in human heart disease. Physiol Genomics 2007;31:367-373. (Pubitemid 350127777)
18. Thum T, Galuppo P,Wolf C, Fiedler J, Kneitz S, van Laake LWet al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007;116: 258-267. (Pubitemid 47196561)
19. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007;100:416-424.
20. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 2007; 170:1831-1840. (Pubitemid 47339258)
21. Gupta SK, Bang C, Thum T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet 2010;3:484-488.
22. Zhu H, Fan GC. Extracellular/circulating microRNAs and their potential role in cardiovascular disease. Am J Cardiovasc Dis 2011;1:138-149.
23. van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007;117:2369-2376. (Pubitemid 47494334)
24. Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res 2008;79:562-570.
25. Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci USA 2007;104:17719-17724. (Pubitemid 350210901)
26. Zhang X, Wang X, Zhu H, Zhu C, Wang Y, Pu WT et al. Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death. J Mol Cell Cardiol 2010;49:841-850.
27. Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, Roeder RG et al. Chromatin structure analyses identify miRNA promoters. Genes Dev 2008;22:3172-3183.
28. Wang JX, Jiao JQ, Li Q, Long B, Wang K, Liu JP et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med 2011;17: 71-78.
29. Bauersachs J, Thum T. Biogenesis and regulation of cardiovascular microRNAs. Circ Res 2011;109:334-347.
30. He B, Xiao J, Ren AJ, Zhang YF, Zhang H, Chen M et al. Role of miR-1 and miR-133a in myocardial ischemic postconditioning. J Biomed Sci 2011;18:22-31.
31. Tang Y, Zheng J, Sun Y, Wu Z, Liu Z, Huang G. MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. Int Heart J 2009;50:377-387.
32. Ren XP,Wu J,Wang X, Sartor MA, Qian J, Jones K et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20 Circulation 2009;119:2357-2366.
33. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009;82: 21-29.
34. Dong S, Cheng Y, Yang J, Li J, Liu X, Wang X et al. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 2009;284:29514-29525.
35. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008;105:13027-13032.
36. Bostjancic E, Zidar N, Glavac D. MicroRNA microarray expression profiling in human myocardial infarction. Dis Markers 2009;27:255-268.
37. Yin C, Salloum FN, Kukreja RC. A novel role of microRNA in late preconditioning: upregulation of endothelial nitric oxide synthase and heat shock protein 70. Circ Res 2009;104:572-575.
38. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006;38:228-233. (Pubitemid 43177239)
39. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005;436:214-220. (Pubitemid 41021266)
40. Sweetman D, Goljanek K, Rathjen T, Oustanina S, Braun T, Dalmay T et al. Specific requirements of MRFs for the expression of muscle specific microRNAs, miR-1, miR-206 and miR-133. Dev Biol 2008;321:491-499.
41. Townley-Tilson WH, Callis TE, Wang D. MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. Int J Biochem Cell Biol 2010;42:1252-1255.
42. Bostjancic E, Zidar N, Stajer D, Glavac D. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology 2010;115: 163-169.
43. Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H et al. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 2007;120:3045-3052. (Pubitemid 47517087)
44. Yu XY, Song YH, Geng YJ, Lin QX, Shan ZX, Lin SG et al. Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1. Biochem Biophys Res Commun 2008; 376:548-552.
45. Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, Condorelli G et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 2010;106:166-175.
46. Terentyev D, Belevych AE, Terentyeva R, Martin MM, Malana GE, Kuhn DE et al. miR-1 overexpression enhances Ca2+ release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56a and causing CaMKII-dependent hyperphosphorylation of RyR2. Circ Res 2009;104:514-521.
47. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007;13:486-491. (Pubitemid 46559834)
48. Lu Y, Zhang Y, Shan H, Pan Z, Li X, Li B et al. MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection. Cardiovasc Res 2009;84:434-441.
49. da Costa Martins PA, De Windt LJ. miR-21: a miRaculous Socratic paradox. Cardiovasc Res 2010;87:397-400.
50. Cheng Y, Zhang C. MicroRNA-21 in cardiovascular disease. J Cardiovasc Transl Res 2010;3:251-255.
51. Sabatel C, Malvaux L, Bovy N, Deroanne C, Lambert V, Gonzalez ML et al. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS One 2011;6:e16979.
52. Cheng Y, Liu X, Zhang S, Lin Y, Yang J, Zhang C. MicroRNA-21 protects against the H2O2-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol 2009;47:5-14.
53. Cheng Y, Zhu P, Yang J, Liu X, Dong S, Wang X et al. Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovasc Res 2010;87:431-439.
54. Sayed D, He M, Hong C, Gao S, Rane S, Yang Z et al. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem 2010;285:20281-20290.
55. Yin C, Wang X, Kukreja RC. Endogenous microRNAs induced by heat-shock reduce myocardial infarction following ischemia-reperfusion in mice. FEBS Lett 2008;582: 4137-4142.
56. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456:980-984.
57. Patrick DM, Montgomery RL, Qi X, Obad S, Kauppinen S, Hill JA et al. Stressdependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 2010;120:3912-3916.
58. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M et al. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 2007;42:1137-1141. (Pubitemid 46829201)
59. Thum T, Chau N, Bhat B, Gupta SK, Linsley PS, Bauersachs J et al. Comparison of different miR-21 inhibitor chemistries in a cardiac disease model. J Clin Invest 2011;121: 461-462.
60. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011;43:371-378.
61. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006;66:11590-11593. (Pubitemid 46094168)
62. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007;26:6133-6140. (Pubitemid 47414372)
63. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J et al. NF-kB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008; 14:369-381.
64. Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 by targeting p85a and CDC42. Nat Struct Mol Biol 2009;16:23-29.
65. Ye Y, Hu Z, Lin Y, Zhang C, Perez-Polo JR. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-g agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res 2010;87:535-544.
66. Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 2011;124: 720-730.
67. Qian L, Van Laake LW, Huang Y, Liu S, Wendland MF, Srivastava D. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J Exp Med 2011;208: 549-560.
68. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 2008;79:581-588.
69. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA 2008;105:1516-1521. (Pubitemid 351346546)
70. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA et al. The endothelialspecific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008;15:261-271.
71. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008;15:272-284.
72. Kuhnert F, Mancuso MR, Hampton J, Stankunas K, Asano T, Chen CZ et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development 2008;135:3989-3993.
73. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009;2:ra81.
74. van Solingen C, Seghers L, Bijkerk R, Duijs JM, Roeten MK, van Oeveren-Rietdijk A et al. Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J Cell Mol Med 2009;13:1577-1585.
75. Zhang Q, Kandic I, Kutryk MJ. Dysregulation of angiogenesis-related microRNAs in endothelial progenitor cells from patients with coronary artery disease. Biochem Biophys Res Commun 2011;405:42-46.
76. Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008;283:15878-15883.
77. Mutharasan RK, Nagpal V, Ichikawa Y, Ardehali H. MicroRNA-210 is upregulated in hypoxic cardiomyocytes through Akt-and p53-dependent pathways and exerts cytoprotective effects. Am J Physiol Heart Circ Physiol 2011;301:H1519-H1530.
78. Kim HW, Haider HK, Jiang S, Ashraf M. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem 2009;284:33161-33168.
79. Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010;122:S124-S131.
80. Wang X, Zhang X, Ren XP, Chen J, Liu H, Yang J et al. MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. Circulation 2010;122:1308-1318.
81. Liu L, Jiang Y, Zhang H, Greenlee AR, Han Z. Overexpressed miR-494 down-regulates PTEN gene expression in cells transformed by anti-benzo(a)pyrene- trans-7,8-dihydrodiol-9,10-epoxide. Life Sci 2010;86:192-198.
82. Shieh JT, Huang Y, Gilmore J, Srivastava D. Elevated miR-499 levels blunt the cardiac stress response. PLoS One 2011;6:e19481.
83. Doebele C, Bonauer A, Fischer A, Scholz A, Reiss Y, Urbich C et al. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood 2010;115:4944-4950.
84. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009;324:1710-1713.
85. Watanabe T, Sato T, Amano T, Kawamura Y, Kawamura N, Kawaguchi H et al. Dnm3os, a non-coding RNA, is required for normal growth and skeletal development in mice. Dev Dyn 2008;237:3738-3748.
86. Lee YB, Bantounas I, Lee DY, Phylactou L, Caldwell MA, Uney JB. Twist-1 regulates the miR-199a/214 cluster during development. Nucleic Acids Res 2009;37:123-128.
87. Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima J et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1a and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2009;104:879-886.
88. Murakami Y, Toyoda H, Tanaka M, Kuroda M, Harada Y, Matsuda F et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One 2011;6:e16081.
89. Wang XH, Qian RZ, Zhang W, Chen SF, Jin HM, Hu RM. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol 2009;36:181-188.
90. Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 2011;51:872-875.
91. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102: 13944-13949. (Pubitemid 41377683)
92. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006;103:12481-12486. (Pubitemid 44267285)
93. Ma X, Becker Buscaglia LE, Barker JR, Li Y. MicroRNAs in NF-kB signaling. J Mol Cell Biol 2011;3:159-166.
94. Hulsmans M, De Keyzer D, Holvoet P. MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis. FASEB J 2011;25:2515-2527.
95. Yu D, dos Santos CO, Zhao G, Jiang J, Amigo JD, Khandros E et al. miR-451 protects against erythroid oxidant stress by repressing 14-3-3z. Genes Dev 2010;24: 1620-1633.
96. Xiao J, Zhu X, He B, Zhang Y, Kang B,Wang Z et al. MiR-204 regulates cardiomyocyte autophagy induced by ischemia-reperfusion through LC3-II. J Biomed Sci 2011;18:35.
97. Dai R, Li J, Liu Y, Yan D, Chen S, Duan C et al. miR-221/222 suppression protects against endoplasmic reticulum stress-induced apoptosis via p27(Kip1)-and MEK/ERKmediated cell cycle regulation. Biol Chem 2010;391:791-801.
98. Frost RJ, van Rooij E. miRNAs as therapeutic targets in ischemic heart disease. J Cardiovasc Transl Res 2010;3:280-289.
99. PollerW, Hajjar R, Schultheiss HP, Fechner H. Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure. Cardiovasc Res 2010;86: 353-364.